Array Biopharma (ARRY) Getting Somewhat Positive Press Coverage, Analysis Shows

Media stories about Array Biopharma (NASDAQ:ARRY) have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Array Biopharma earned a news sentiment score of 0.14 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 44.8943669789636 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Here are some of the news stories that may have effected Accern Sentiment’s analysis:

How to Become a New Pot Stock Millionaire

ARRY has been the topic of a number of recent analyst reports. Leerink Swann upgraded Array Biopharma from a “market perform” rating to an “outperform” rating in a report on Monday, January 22nd. BidaskClub lowered Array Biopharma from a “hold” rating to a “sell” rating in a report on Wednesday, March 21st. SunTrust Banks reiterated a “buy” rating and set a $20.00 price target on shares of Array Biopharma in a report on Tuesday, February 6th. Jefferies Group lifted their price target on Array Biopharma to $13.00 and gave the stock a “buy” rating in a report on Friday, December 22nd. Finally, ValuEngine upgraded Array Biopharma from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Array Biopharma has an average rating of “Buy” and a consensus price target of $17.25.

NASDAQ:ARRY opened at $14.94 on Monday. The company has a debt-to-equity ratio of 0.39, a current ratio of 6.17 and a quick ratio of 6.17. Array Biopharma has a 1 year low of $6.73 and a 1 year high of $18.78. The firm has a market capitalization of $3,102.10, a price-to-earnings ratio of -20.75 and a beta of 1.73.

Array Biopharma (NASDAQ:ARRY) last released its earnings results on Tuesday, February 6th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.23) by $0.06. Array Biopharma had a negative return on equity of 107.79% and a negative net margin of 98.51%. The business had revenue of $42.21 million during the quarter, compared to the consensus estimate of $26.81 million. During the same period last year, the business posted ($0.14) earnings per share. The business’s revenue for the quarter was down 5.2% on a year-over-year basis. equities research analysts predict that Array Biopharma will post -0.88 EPS for the current fiscal year.

In other Array Biopharma news, Director Lunsen Gil J. Van sold 21,500 shares of the firm’s stock in a transaction on Wednesday, March 21st. The stock was sold at an average price of $16.76, for a total value of $360,340.00. Following the completion of the sale, the director now directly owns 26,297 shares of the company’s stock, valued at $440,737.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Victor Sandor sold 8,689 shares of the firm’s stock in a transaction on Tuesday, April 3rd. The stock was sold at an average price of $15.35, for a total value of $133,376.15. The disclosure for this sale can be found here. Insiders sold 286,705 shares of company stock valued at $4,851,885 over the last three months. Company insiders own 3.18% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece was posted by Ticker Report and is owned by of Ticker Report. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of international trademark and copyright law. The correct version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3342401/array-biopharma-arry-getting-somewhat-positive-press-coverage-analysis-shows.html.

Array Biopharma Company Profile

Array BioPharma Inc is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company’s programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC).

Insider Buying and Selling by Quarter for Array Biopharma (NASDAQ:ARRY)

Receive News & Ratings for Array Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Array Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Ninetowns Internet Technlgy Grp  Receiving Somewhat Favorable Media Coverage, Study Finds
Ninetowns Internet Technlgy Grp Receiving Somewhat Favorable Media Coverage, Study Finds
EA Coin Trading Up 27% This Week
EA Coin Trading Up 27% This Week
Financial Survey: Five Below  & Dollar General
Financial Survey: Five Below & Dollar General
Critical Comparison: Alphabet  vs. Its Rivals
Critical Comparison: Alphabet vs. Its Rivals
Financial Contrast: Hilton Grand Vacations  versus Civeo
Financial Contrast: Hilton Grand Vacations versus Civeo
Zacks: Fennec Pharmaceuticals Inc  Given $17.50 Average Price Target by Analysts
Zacks: Fennec Pharmaceuticals Inc Given $17.50 Average Price Target by Analysts


Leave a Reply

© 2006-2018 Ticker Report. Google+.